Home / What’s new? / Patents

Patents

Sort by:
YearTitle
DescendingAscending

Patent

NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

Number
WO 2020/089453 A1
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

Novel Indolizine-2-carboxamides active against the Hepatitis B virus (HBV)

Number
WO 2020/221824
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv)

Number
WO 2020/221816
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

Novel sulfonamideurea compounds

Number
WO2020/035464 A1
Year
2020
Customer
Inflamazone
Site
Groningen
Department
Discovery
MCS People
Jim van Wiltenburg
Patent

Novel sulfonamidocarboxamide compounds as NLRP3 inhibitors and their preparation

Number
WO 2019/008025 A1
Year
2020
Customer
Inflamazone
Site
Groningen
Department
Discovery
MCS People
Jim van Wiltenburg
Patent

NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

Number
WO 2020/089456 A1WO 2020/089459 A1
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

Number
WO 2020/089452 A1
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

NOVEL UREA 6,7-DIHYDRO-4H-THIAZOLO[5,4-C]PYRIDINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

Number
WO 2020/089460 A1
Year
2020
Customer
AiCuris
Site
Nijmegen
Department
Discovery
MCS People
Jasper Springer
Patent

paration of substituted sulfonyl triazoles and related heteroaryl compounds as as NLRP3 inhibitors usefulin treatment and prevention of diseases

Number
WO 2019/211463 A1
Year
2020
Customer
Inflamazone
Site
Groningen
Department
Discovery
MCS People
Jim van Wiltenburg, Jack den Hartog
Patent

Preparation of novel sulfonamide carboxamide compounds as NLRP3 inhibitors

Number
WO 2019/034696 A1WO 2019/034697 A1WO 2019/034686 A1
Year
2020
Customer
Inflamazone
Site
Groningen
Department
Discovery
MCS People
Jim van Wiltenburg

* indicates required



 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
 
 

Development Centres of Excellence Network Lead Optimization Hit Generation Lead Optimization
 
 
 
Scroll to top